These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor. Yamada T; Tomioka K; Saito M; Horie M; Mase T; Hara H; Nagaoka H Arch Int Pharmacodyn Ther; 1990; 308():123-36. PubMed ID: 2099131 [TBL] [Abstract][Full Text] [Related]
6. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride. Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist. Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114 [TBL] [Abstract][Full Text] [Related]
8. Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat. Toth PD; Mikulaschek AW Circ Shock; 1986; 20(3):193-203. PubMed ID: 3802423 [TBL] [Abstract][Full Text] [Related]
9. Effect of the platelet activating factor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride on endotoxin-induced hypotension and hematological parameters in rats. Natsume Y; Imanishi N; Koike H; Morooka S Arzneimittelforschung; 1994 Nov; 44(11):1208-13. PubMed ID: 7848333 [TBL] [Abstract][Full Text] [Related]
10. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Dhainaut JF; Tenaillon A; Le Tulzo Y; Schlemmer B; Solet JP; Wolff M; Holzapfel L; Zeni F; Dreyfuss D; Mira JP Crit Care Med; 1994 Nov; 22(11):1720-8. PubMed ID: 7956274 [TBL] [Abstract][Full Text] [Related]
11. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Dhainaut JF; Tenaillon A; Hemmer M; Damas P; Le Tulzo Y; Radermacher P; Schaller MD; Sollet JP; Wolff M; Holzapfel L; Zeni F; Vedrinne JM; de Vathaire F; Gourlay ML; Guinot P; Mira JP Crit Care Med; 1998 Dec; 26(12):1963-71. PubMed ID: 9875905 [TBL] [Abstract][Full Text] [Related]
12. Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists. Wallace JL; Steel G; Whittle BJ; Lagente V; Vargaftig B Gastroenterology; 1987 Oct; 93(4):765-73. PubMed ID: 3305134 [TBL] [Abstract][Full Text] [Related]
13. Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist. Handley DA; Van Valen RG; Melden MK; Flury S; Lee ML; Saunders RN Immunopharmacology; 1986 Aug; 12(1):11-6. PubMed ID: 3019921 [TBL] [Abstract][Full Text] [Related]
14. Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats. Qi M; Jones SB Circ Shock; 1990 Oct; 32(2):153-63. PubMed ID: 2253318 [TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal plasma leakage in endotoxic shock. Inhibition by prostaglandin E2 and by a platelet-activating factor antagonist. Wallace JL; Steel G; Whittle BJ Can J Physiol Pharmacol; 1987 Jul; 65(7):1428-32. PubMed ID: 3478114 [TBL] [Abstract][Full Text] [Related]
16. Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock. Casals-Stenzel J Eur J Pharmacol; 1987 Mar; 135(2):117-22. PubMed ID: 3582490 [TBL] [Abstract][Full Text] [Related]
17. Beneficial effect of a platelet-activating factor antagonist, WEB 2086, on endotoxin-induced lung injury. Chang SW; Fernyak S; Voelkel NF Am J Physiol; 1990 Jan; 258(1 Pt 2):H153-8. PubMed ID: 2301603 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies. Fernández-Gallardo S; Ortega MP; Priego JG; de Casa-Juana MF; Sunkel C; Sánchez Crespo M J Pharmacol Exp Ther; 1990 Oct; 255(1):34-9. PubMed ID: 2170626 [TBL] [Abstract][Full Text] [Related]
19. Octylonium bromide, an antagonist of platelet-activating factor. Subissi A; Del Monte M; Evangelista S; Santicioli P; Criscuoli M Arch Int Pharmacodyn Ther; 1989; 302():255-67. PubMed ID: 2636821 [TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models. Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]